{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:54:11Z","timestamp":1791309251009,"version":"4.3.1"},"reference-count":81,"publisher":"Galenos Yayinevi","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjps"],"published-print":{"date-parts":[[2022,6,27]]},"DOI":"10.4274\/tjps.galenos.2021.95226","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T13:51:19Z","timestamp":1623246679000},"page":"343-352","source":"Crossref","is-referenced-by-count":10,"title":["Non-Oral Drug Delivery in Parkinson\u2019s Disease: Current Applications and Future"],"prefix":"10.4274","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4440-494X","authenticated-orcid":false,"given":"Meliha","family":"G\u00dcNE\u015e","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6010-5902","authenticated-orcid":false,"given":"Sinem Yaprak","family":"KARAVANA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","unstructured":"1. Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27:27-42.","journal-title":"Eur J Neurol"},{"key":"ref1","unstructured":"2. What is Parkinson's? | American Parkinson Disease Assoc. Published 2020. Accessed: March 18, 2020. Available from: https:\/\/www.apdaparkinson.org\/what-is-parkinsons\/"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Pfeiffer RF. Non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2016;22(Suppl 1):S119-S122.","DOI":"10.1016\/j.parkreldis.2015.09.004"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Parkinsonism Relat Disord. 2009;15(Suppl 1):S9-S15.","DOI":"10.1016\/S1353-8020(09)70005-7"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"BS","year":"2014","unstructured":"5. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311:1670-1683.","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.12968\/npre.2018.16.1.26","article-title":"The use of non-oral therapies in Parkinson's disease","volume":"16","author":"Price","year":"2018","unstructured":"6. Price J, Martin H, Ebenezer L. The use of non-oral therapies in Parkinson's disease. J Prescr Prac. 2018;16:26-30.","journal-title":"J Prescr Prac"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson's disease on the quality of life","volume":"20","author":"Chapuis","year":"2005","unstructured":"7. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord. 2005;20:224-230.","journal-title":"Mov Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.parkreldis.2014.09.013","article-title":"Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study","volume":"20","author":"Rizos","year":"2014","unstructured":"8. Rizos A, Martinez-Martin P, Odin P, Antonini A, Kessel B, Kozul TK, Todorova A, Douiri A, Martin A, Stocchi F, Dietrichs E, Chaudhuri KR; EUROPAR and the IPDMDS non-Motor PD Study Group. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study. Parkinsonism Relat Disord. 2014;20:1231-1235.","journal-title":"Parkinsonism Relat Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"14","author":"Fasano","year":"2015","unstructured":"9. Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2015;14:625-639.","journal-title":"Lancet Neurol"},{"key":"ref9","unstructured":"10. What is Parkinson's? | European Parkinson's Disease AssociationAccessed March 28, 2021. Available from: https:\/\/www.epda.eu.com\/about-parkinsons\/what-is-parkinsons\/"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/JPD-130186","article-title":"Levodopa in the treatment of Parkinson's disease: current status and new developments","volume":"3","author":"Salat","year":"2013","unstructured":"11. Salat D, Tolosa E. Levodopa in the treatment of Parkinson's disease: current status and new developments. J Parkinsons Dis. 2013;3:255-269.","journal-title":"J Parkinsons Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0037-1602423","article-title":"Motor complications of dopaminergic medications in Parkinson's disease","volume":"37","author":"Freitas","year":"2017","unstructured":"12. Freitas ME, Hess CW, Fox SH. Motor complications of dopaminergic medications in Parkinson's disease. Semin Neurol. 2017;37:147-157.","journal-title":"Semin Neurol"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. van Laar T, Borgemeester R. The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine. Parkinsonism Relat Disord. 2016;33(Suppl 1):S22-S27.","DOI":"10.1016\/j.parkreldis.2016.11.019"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2147\/NDT.S157731","article-title":"Cytological and cytometric analysis of oral mucosa in patients with Alzheimer's and Parkinson's disease","volume":"14","author":"Ozlece","year":"2018","unstructured":"14. Ozlece HK, Guvendi GF, Huseyinoglu N, Ehi Y, Kivrak Y. Cytological and cytometric analysis of oral mucosa in patients with Alzheimer's and Parkinson's disease. Neuropsychiatr Dis Treat. 2018;14:1901-1906.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol. 2010;63:257-266.","DOI":"10.1159\/000300647"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/mds.25708","article-title":"Delayed gastric emptying in Parkinson's disease","volume":"29","author":"Marrinan","year":"2014","unstructured":"16. Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson's disease. Mov Disord. 2014;29:23-32.","journal-title":"Mov Disord"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1474-4422(03)00307-7","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"2","author":"Pfeiffer","year":"2003","unstructured":"17. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2003;2:107-116.","journal-title":"Lancet Neurol"},{"key":"ref17","unstructured":"18. Goldenberg MM. Medical management of Parkinson's disease. P T. 2008;33:590-606."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1212\/01.WNL.0000044047.58984.2F","article-title":"Slowing Parkinson's disease progression: recent dopamine agonist trials","volume":"60","author":"Ahlskog","year":"2003","unstructured":"19. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2003;60:381-389.","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/B978-0-12-381326-8.00009-0","article-title":"Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease","volume":"95","author":"Kaakkola","year":"2010","unstructured":"20. Kaakkola S. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. Int Rev Neurobiol. 2010;95:207-225.","journal-title":"Int Rev Neurobiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2165\/00003495-200059060-00004","article-title":"Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease","volume":"59","author":"Kaakkola","year":"2000","unstructured":"21. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000;59:1233-1250.","journal-title":"Drugs"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/187152712800672436","article-title":"Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment","volume":"11","author":"Espinoza","year":"2012","unstructured":"22. Espinoza S, Manago F, Leo D, Sotnikova TD, Gainetdinov RR. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment. CNS Neurol Disord Drug Targets. 2012;11:251-263.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref22","unstructured":"23. DeMaagd G, Philip A. Parkinson' disease and its management: part 3: nondopaminergic and nonpharmacological treatment options. P T. 2015;40:668-679."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/1871524919666181126124846","article-title":"Development and characterization of nasal delivery of selegiline hydrochloride loaded nanolipid carriers for the management of Parkinson's disease","volume":"19","author":"Mishra","year":"2019","unstructured":"24. Mishra N, Sharma S, Deshmukh R, Kumar A, Sharma R. Development and characterization of nasal delivery of selegiline hydrochloride loaded nanolipid carriers for the management of Parkinson's disease. Cent Nerv Syst Agents Med Chem. 2019;19:46-56.","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00702-003-0042-6","article-title":"A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition","volume":"110","author":"Clarke","year":"2003","unstructured":"25. Clarke A, Johnson ES, Mallard N, Corn TH, Johnston A, Boyce M, Warrington S, MacMahon DG. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm (Vienna). 2003;110:1257-1271.","journal-title":"J Neural Transm (Vienna)"},{"key":"ref25","unstructured":"26. Lee KC, Chen JJ. Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3:527-537."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00702-012-0927-3","article-title":"Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease","volume":"120","author":"M\u00fcller","year":"2013","unstructured":"27. M\u00fcller T, Hoffmann JA, Dimpfel W, Oehlwein C. Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease. J Neural Transm (Vienna). 2013;120:761-765.","journal-title":"J Neural Transm (Vienna)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/B978-0-12-386467-3.00009-1","article-title":"Selective inhibitors of monoamine oxidase type B and the \"cheese effect\"","volume":"100","author":"JP","year":"2011","unstructured":"28. Finberg JP, Gillman K. Selective inhibitors of monoamine oxidase type B and the \"cheese effect\". Int Rev Neurobiol. 2011;100:169-190.","journal-title":"Int Rev Neurobiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1177\/0091270010369674","article-title":"Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline","volume":"50","author":"Goren","year":"2010","unstructured":"29. Goren T, Adar L, Sasson N, Weiss YM. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol. 2010;50:1420-1428.","journal-title":"J Clin Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/mds.21048","article-title":"Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline","volume":"21","author":"JA","year":"2006","unstructured":"30. deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I; Parkinson Study Group TEMPO; PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21:1716-1721.","journal-title":"Mov Disord"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/JEP.S267032","article-title":"Experimental dopamine reuptake inhibitors in Parkinson's disease: a review of the evidence","volume":"13","author":"M\u00fcller","year":"2021","unstructured":"31. M\u00fcller T. Experimental dopamine reuptake inhibitors in Parkinson's disease: a review of the evidence. J Exp Pharmacol. 2021;13:397-408.","journal-title":"J Exp Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Pagliaro LA, Pagliaro AM. Levodopa [L-Dopa]. In: PNDR: Psychologists' neuropsychotropic drug reference. Routledge; 2020:185-189.","DOI":"10.4324\/9781315825748-35"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00455-015-9671-9","article-title":"Dysphagia in Parkinson's disease","volume":"31","author":"Suttrup","year":"2016","unstructured":"33. Suttrup I, Warnecke T. Dysphagia in Parkinson's disease. Dysphagia. 2016;31:24-32.","journal-title":"Dysphagia"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.parkreldis.2011.11.006","article-title":"Prevalence of oropharyngeal dysphagia in Parkinson's disease: a meta-analysis","volume":"18","author":"Kalf","year":"2012","unstructured":"34. Kalf JG, de Swart BJ, Bloem BR, Munneke M. Prevalence of oropharyngeal dysphagia in Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord. 2012;18:311-315.","journal-title":"Parkinsonism Relat Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.clinph.2010.11.002","article-title":"Dysfunction of bulbar central pattern generator in ALS patients with dysphagia during sequential deglutition","volume":"122","author":"Aydogdu","year":"2011","unstructured":"35. Aydogdu I, Tanriverdi Z, Ertekin C. Dysfunction of bulbar central pattern generator in ALS patients with dysphagia during sequential deglutition. Clin Neurophysiol. 2011;122:1219-1228.","journal-title":"Clin Neurophysiol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/mds.21362","article-title":"Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease","volume":"22","author":"Lam","year":"2007","unstructured":"36. Lam K, Lam FK, Lau KK, Chan YK, Kan EY, Woo J, Wong FK, Ko A. Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease. Mov Disord. 2007;22:640-644.","journal-title":"Mov Disord"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.parkreldis.2009.12.003","article-title":"The impact of and the factors associated with drooling in Parkinson's disease","volume":"16","author":"Leibner","year":"2010","unstructured":"37. Leibner J, Ramjit A, Sedig L, Dai Y, Wu SS, Jacobson C, Okun MS, Rodriguez RL, Malaty IA, Fernandez HH. The impact of and the factors associated with drooling in Parkinson's disease. Parkinsonism Relat Disord. 2010;16:475-477.","journal-title":"Parkinsonism Relat Disord"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/mds.23387","article-title":"Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild","volume":"26","author":"M\u00fcller B","year":"2011","unstructured":"38. M\u00fcller B, Larsen JP, Wentzel-Larsen T, Skeie GO, Tysnes OB; Parkwest Study Group. Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild. Mov Disord. 2011;26:65-72.","journal-title":"Mov Disord"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jns.2012.05.010","article-title":"Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease","volume":"319","author":"Doi","year":"2012","unstructured":"39. Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, Tateno F, Tsuyusaki Y, Takahashi O. Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. J Neurol Sci. 2012;319:86-88.","journal-title":"J Neurol Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00415-010-5769-z","article-title":"Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the 13C-acetate breath test","volume":"258","author":"Tanaka","year":"2011","unstructured":"40. Tanaka Y, Kato T, Nishida H, Yamada M, Koumura A, Sakurai T, Hayashi Y, Kimura A, Hozumi I, Araki H, Murase M, Nagaki M, Moriwaki H, Inuzuka T. Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the 13C-acetate breath test. J Neurol. 2011;258:421-426.","journal-title":"J Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.neulet.2004.11.007","article-title":"Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test","volume":"375","author":"Goetze","year":"2005","unstructured":"41. Goetze O, Wieczorek J, Mueller T, Przuntek H, Schmidt WE, Woitalla D. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci Lett. 2005;375:170-173.","journal-title":"Neurosci Lett"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1002\/mds.23933","article-title":"Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test","volume":"26","author":"Unger","year":"2011","unstructured":"42. Unger MM, M\u00f6ller JC, Mankel K, Schmittinger K, Eggert KM, Stamelou M, Stiasny-Kolster K, Bohne K, Bodden M, Mayer G, Oertel WH, Tebbe JJ. Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test. Mov Disord. 2011;26:2559-2563.","journal-title":"Mov Disord"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.parkreldis.2014.02.019","article-title":"Small intestinal bacterial overgrowth in Parkinson's disease","volume":"20","author":"Tan","year":"2014","unstructured":"43. Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, Ng SW, Ang SP, Chow SK, Tan CT, Yong HS, Marras C, Fox SH, Lim SY. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord. 2014;20:535-540.","journal-title":"Parkinsonism Relat Disord"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/mds.25522","article-title":"The role of small intestinal bacterial overgrowth in Parkinson's disease","volume":"28","author":"Fasano","year":"2013","unstructured":"44. Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, Barbaro F, Piano C, Fortuna S, Tortora A, Di Giacopo R, Campanale M, Gigante G, Lauritano EC, Navarra P, Marconi S, Gasbarrini A, Bentivoglio AR. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord. 2013;28:1241-1249.","journal-title":"Mov Disord"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.parkreldis.2007.09.002","article-title":"Nonmotor symptoms of Parkinson's disease: prevalence and awareness of patients and families","volume":"14","author":"Cheon","year":"2008","unstructured":"45. Cheon SM, Ha MS, Park MJ, Kim JW. Nonmotor symptoms of Parkinson's disease: prevalence and awareness of patients and families. Parkinsonism Relat Disord. 2008;14:286-290.","journal-title":"Parkinsonism Relat Disord"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/mds.23566","article-title":"Prevalence of small intestinal bacterial overgrowth in Parkinson's disease","volume":"26","author":"Gabrielli","year":"2011","unstructured":"46. Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A, Ceravolo MG, Capecci M, Rita Bentivoglio A, Provinciali L, Tonali PA, Gasbarrini A. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord. 2011;26:889-892.","journal-title":"Mov Disord"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"16023","DOI":"10.1038\/npjparkd.2016.23","article-title":"Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the future","volume":"2","author":"Ray Chaudhuri","year":"2016","unstructured":"47. Ray Chaudhuri K, Qamar MA, Rajah T, Loehrer P, Sauerbier A, Odin P, Jenner P. Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the future. NPJ Parkinsons Dis. 2016;2:16023.","journal-title":"NPJ Parkinsons Dis"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48. Lomax AE, Linden DR, Mawe GM, Sharkey KA. Effects of gastrointestinal inflammation on enteroendocrine cells and enteric neural reflex circuits. Auton Neurosci. 2006;126-127:250-257.","DOI":"10.1016\/j.autneu.2006.02.015"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1136\/jnnp.2003.034553","article-title":"Delayed early morning turn \"ON\" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be considered","volume":"75","author":"Chan\u00e1","year":"2004","unstructured":"49. Chan\u00e1 P, Kuntsmann C, Reyes-Parada M, S\u00e1ez-Briones P. Delayed early morning turn \"ON\" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be considered. J Neurol Neurosurg Psychiatry. 2004;75:1782-1783.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50. Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One. 2011;6:e28032.","DOI":"10.1371\/journal.pone.0028032"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41467-019-08294-y","article-title":"Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease","volume":"10","author":"van Kessel","year":"2019","unstructured":"51. van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun. 2019;10:310.","journal-title":"Nat Commun"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/mds.26942","article-title":"Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome","volume":"32","author":"Hill-Burns","year":"2017","unstructured":"52. Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov Disord. 2017;32:739-749.","journal-title":"Mov Disord"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/mds.20054","article-title":"Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease","volume":"19","author":"Priano","year":"2004","unstructured":"53. Priano L, Albani G, Brioschi A, Calderoni S, Lopiano L, Rizzone M, Cavalli R, Gasco MR, Scaglione F, Fraschini F, Bergamasco B, Mauro A. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease. Mov Disord. 2004;19:937-942.","journal-title":"Mov Disord"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/mds.22922","article-title":"Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study","volume":"25","author":"Rascol","year":"2010","unstructured":"54. Rascol O, Azulay JP, Blin O, Bonnet AM, Brefel-Courbon C, C\u00e9saro P, Damier P, Debilly B, Durif F, Galitzky M, Grouin JM, Pennaforte S, Villafane G, Yaici S, Agid Y. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study. Mov Disord. 2010;25:368-376.","journal-title":"Mov Disord"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s11095-017-2162-y","article-title":"Continuous transdermal delivery of L-DOPA based on a self-assembling nanomicellar system","volume":"34","author":"Sintov","year":"2017","unstructured":"55. Sintov AC, Levy HV, Greenberg I. Continuous transdermal delivery of L-DOPA based on a self-assembling nanomicellar system. Pharm Res. 2017;34:1459-1468.","journal-title":"Pharm Res"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3109\/10717544.2014.948644","article-title":"Development and evaluation of buccal films impregnated with selegiline-loaded nanospheres","volume":"23","author":"Al-Dhubiab","year":"2016","unstructured":"56. Al-Dhubiab BE, Nair AB, Kumria R, Attimarad M, Harsha S. Development and evaluation of buccal films impregnated with selegiline-loaded nanospheres. Drug Deliv. 2016;23:2154-2162.","journal-title":"Drug Deliv"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3109\/10717544.2013.860501","article-title":"Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization","volume":"22","author":"Ravi","year":"2015","unstructured":"57. Ravi PR, Aditya N, Patil S, Cherian L. Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug Deliv. 2015;22:903-910.","journal-title":"Drug Deliv"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1080\/03639045.2017.1349785","article-title":"Optimization of piribedil mucoadhesive tablets for efficient therapy of Parkinson's disease: physical characterization and ex vivo drug permeation through buccal mucosa","volume":"43","author":"\u00c7elik","year":"2017","unstructured":"58. \u00c7elik B, \u00d6zdemir S, Barla Demirkoz A, \u00dcner M. Optimization of piribedil mucoadhesive tablets for efficient therapy of Parkinson's disease: physical characterization and ex vivo drug permeation through buccal mucosa. Drug Dev Ind Pharm. 2017;43:1836-1845.","journal-title":"Drug Dev Ind Pharm"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.2147\/IJN.S120939","article-title":"Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment","volume":"11","author":"Bi","year":"2016","unstructured":"59. Bi C, Wang A, Chu Y, Liu S, Mu H, Liu W, Wu Z, Sun K, Li Y. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment. Int J Nanomedicine. 2016;11:6547-6559.","journal-title":"Int J Nanomedicine"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"60. Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov Disord. 2008;23(Suppl 3):S599-S612.","DOI":"10.1002\/mds.22052"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"61. Wang L, Li J, Chen J. Levodopa-carbidopa intestinal gel in Parkinson's disease: a systematic review and meta-analysis. Front Neurol. 2018;9.","DOI":"10.3389\/fneur.2018.00620"},{"key":"ref61","unstructured":"62. G\u00fcltekin M, Ulukan \u00c7, Tezcan S, Do\u011fu O, Hana\u011fasi H, Bilgi\u00e7 B, Bora Tok\u00e7aer A, \u00c7akmur R, Elibol B, Mirza M, \u0130nce G\u00fcnal D, Erer \u00d6zbek \u00c7S, Kenangil G, Yilmaz K\u00fcsbeci \u00d6, Akbostanci MC. Multicenter study of levodopa carbidopa intestinal gel in Parkinson's disease: the Turkish experience. Turk J Med Sci. 2020;50:66-85."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.26855","article-title":"Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: a randomized crossover study","volume":"32","author":"Senek","year":"2017","unstructured":"63. Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: a randomized crossover study. Mov Disord. 2017;32:283-286.","journal-title":"Mov Disord"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1468-1331.2011.03614.x","article-title":"Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial","volume":"19","author":"Nyholm","year":"2012","unstructured":"64. Nyholm D, Johansson A, Lennern\u00e4s H, Askmark H. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Eur J Neurol. 2012;19:820-826.","journal-title":"Eur J Neurol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","article-title":"Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial","volume":"15","author":"JJ","year":"2016","unstructured":"65. Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154-165.","journal-title":"Lancet Neurol"},{"key":"ref65","unstructured":"66. Drug Approval Package: Inbrija."},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"67. Lipp MM, Batycky R, Moore J, Leinonen M, Freed MI. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease. Sci Transl Med. 2016;8:360ra136.","DOI":"10.1126\/scitranslmed.aad8858"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"2040622319857617","DOI":"10.1177\/2040622319857617","article-title":"Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease","volume":"10","author":"Luinstra","year":"2019","unstructured":"68. Luinstra M, Rutgers W, van Laar T, Grasmeijer F, Begeman A, Isufi V, Steenhuis L, Hagedoorn P, de Boer A, Frijlink HW. Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease. Ther Adv Chronic Dis. 2019;10:2040622319857617.","journal-title":"Ther Adv Chronic Dis"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40263-019-00646-y","article-title":"Rotigotine transdermal patch: a review in Parkinson's disease","volume":"33","author":"Frampton","year":"2019","unstructured":"69. Frampton JE. Rotigotine transdermal patch: a review in Parkinson's disease. CNS Drugs. 2019;33:707-718.","journal-title":"CNS Drugs"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23441","article-title":"Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)","volume":"26","author":"Trenkwalder","year":"2011","unstructured":"70. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR; Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90-99.","journal-title":"Mov Disord"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/ene.13034","article-title":"A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists","volume":"23","author":"Rizos","year":"2016","unstructured":"71. Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, Henriksen T, Falup-Pecurariu C, Silverdale M, Durner G, R\u00f8kenes Karlsen K, Grilo M, Odin P, Chaudhuri KR; EUROPAR and the IPMDS Non-Motor-PD-Study Group. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016;23:1255-1261.","journal-title":"Eur J Neurol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.parkreldis.2013.02.018","article-title":"Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER","volume":"19","author":"Ray Chaudhuri","year":"2013","unstructured":"72. Ray Chaudhuri K, Martinez-Martin P, Antonini A, Brown RG, Friedman JH, Onofrj M, Surmann E, Ghys L, Trenkwalder C. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19:660-665.","journal-title":"Parkinsonism Relat Disord"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/mds.25625","article-title":"Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit","volume":"28","author":"Eskow Jaunarajs","year":"2013","unstructured":"73. Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit. Mov Disord. 2013;28:1675-1682.","journal-title":"Mov Disord"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/mds.28027","article-title":"Once-weekly subcutaneous delivery of polymer-linked rotigotine (SER-214) provides continuous plasma levels in Parkinson's disease patients","volume":"35","author":"Olanow","year":"2020","unstructured":"74. Olanow CW, Standaert DG, Kieburtz K, Viegas TX, Moreadith R. Once-weekly subcutaneous delivery of polymer-linked rotigotine (SER-214) provides continuous plasma levels in Parkinson's disease patients. Mov Disord. 2020;35:1055-1061.","journal-title":"Mov Disord"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/mdc3.12350","article-title":"Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson's disease","volume":"4","author":"Isaacson","year":"2017","unstructured":"75. Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson's disease. Mov Disord Clin Pract. 2017;4:78-83.","journal-title":"Mov Disord Clin Pract"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2165\/00002512-200421110-00001","article-title":"Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease","volume":"21","author":"Deleu","year":"2004","unstructured":"76. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging. 2004;21:687-709.","journal-title":"Drugs Aging"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/JPD-120142","article-title":"Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study","volume":"3","author":"Grosset","year":"2013","unstructured":"77. Grosset KA, Malek N, Morgan F, Grosset DG. Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study. J Parkinsons Dis. 2013;3:31-37.","journal-title":"J Parkinsons Dis"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/ane.12107","article-title":"Inhaled dry powder apomorphine (VR040) for 'off' periods in Parkinson's disease: an in-clinic double-blind dose ranging study","volume":"128","author":"Grosset","year":"2013","unstructured":"78. Grosset KA, Malek N, Morgan F, Grosset DG. Inhaled dry powder apomorphine (VR040) for 'off' periods in Parkinson's disease: an in-clinic double-blind dose ranging study. Acta Neurol Scand. 2013;128:166-171.","journal-title":"Acta Neurol Scand"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/mds.26697","article-title":"Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease","volume":"31","author":"Hauser","year":"2016","unstructured":"79. Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, Dubow J, Agro A. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. Mov Disord. 2016;31:1366-1372.","journal-title":"Mov Disord"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00702-003-0036-4","article-title":"A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition","volume":"110","author":"Clarke","year":"2003","unstructured":"80. Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F, Taylor S, Corn TH. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm (Vienna). 2003;110:1241-1255.","journal-title":"J Neural Transm (Vienna)"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mds.20036","article-title":"Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study","volume":"19","author":"CH","year":"2004","unstructured":"81. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM; Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426-432.","journal-title":"Mov Disord"}],"container-title":["Turkish Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T12:59:19Z","timestamp":1717678759000},"score":1,"resource":{"primary":{"URL":"https:\/\/turkjps.org\/articles\/doi\/tjps.galenos.2021.95226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,27]]},"published-print":{"date-parts":[[2022,6,27]]}},"URL":"https:\/\/doi.org\/10.4274\/tjps.galenos.2021.95226","relation":{},"ISSN":["1304-530X","2148-6247"],"issn-type":[{"value":"1304-530X","type":"print"},{"value":"2148-6247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]}}}